Glucagon-like peptide 1--a cardiologic dimension

Marek Treiman; Mikkel Elvekjaer; Thomas Engstrøm; Jan Skov Jensen

doi:10.1016/j.tcm.2010.02.012

Glucagon-like peptide 1--a cardiologic dimension

Marek Treiman, Mikkel Elvekjaer, Thomas Engstrøm, Jan Skov Jensen

24 Citationer (Scopus)

Abstract

Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.

Originalsprog	Engelsk
Tidsskrift	Trends in Cardiovascular Medicine
Vol/bind	20
Udgave nummer	1
Sider (fra-til)	8-12
Antal sider	5
ISSN	1050-1738
DOI	https://doi.org/10.1016/j.tcm.2010.02.012
Status	Udgivet - 1 jan. 2010

Adgang til dokumentet

10.1016/j.tcm.2010.02.012

Citationsformater

@article{73703bd9e57b4fa8bb95188f98168e20,

title = "Glucagon-like peptide 1--a cardiologic dimension",

abstract = "Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.",

keywords = "Animals, Blood Pressure, Cardiovascular Agents, Glucagon-Like Peptide 1, Heart Diseases, Humans, Myocardial Contraction, Myocardial Reperfusion Injury, Signal Transduction, Treatment Outcome, Vasodilation, Ventricular Function, Left",

author = "Marek Treiman and Mikkel Elvekjaer and Thomas Engstr{\o}m and Jensen, {Jan Skov}",

year = "2010",

month = jan,

day = "1",

doi = "10.1016/j.tcm.2010.02.012",

language = "English",

volume = "20",

pages = "8--12",

journal = "Trends in Cardiovascular Medicine",

issn = "1050-1738",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Glucagon-like peptide 1--a cardiologic dimension

AU - Treiman, Marek

AU - Elvekjaer, Mikkel

AU - Engstrøm, Thomas

AU - Jensen, Jan Skov

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.

AB - Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.

KW - Animals

KW - Blood Pressure

KW - Cardiovascular Agents

KW - Glucagon-Like Peptide 1

KW - Heart Diseases

KW - Humans

KW - Myocardial Contraction

KW - Myocardial Reperfusion Injury

KW - Signal Transduction

KW - Treatment Outcome

KW - Vasodilation

KW - Ventricular Function, Left

U2 - 10.1016/j.tcm.2010.02.012

DO - 10.1016/j.tcm.2010.02.012

M3 - Journal article

C2 - 20685571

SN - 1050-1738

VL - 20

SP - 8

EP - 12

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

IS - 1

ER -

Glucagon-like peptide 1--a cardiologic dimension

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater